The DOI matches its Crossref record.
Oxaliplatin–Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study
Abstract
Conventional chemotherapy against colorectal cancer (CRC), the third most common cancer in the world, includes oxaliplatin (Oxa) which induces serious unwanted side effects that limit the efficiency of treatment. Therefore, alternative therapeutic approaches are urgently required. In this work, biomimetic magnetic nanoparticles (BMNPs) mediated by MamC were coupled to Oxa to evaluate the potential of the Oxa–BMNP nanoassembly for directed local delivery of the drug as a proof of concept for the future development of targeted chemotherapy against CRC. Electrostatic interactions between Oxa and BMNPs trigger the formation of the nanoassembly and keep it stable at physiological pH. When the BMNPs become neutral at acidic pH values, the Oxa is released, and such a release is greatly potentiated by hyperthermia. The coupling of the drug with the BMNPs improves its toxicity to even higher levels than the soluble drug, probably because of the fast internalization of the nanoassembly by tumor cells through endocytosis. In addition, the BMNPs are cytocompatible and non-hemolytic, providing positive feedback as a proof of concept for the nanoassembly. Our study clearly demonstrates the applicability of Oxa–BMNP in colon cancer and offers a promising nanoassembly for targeted chemotherapy against this type of tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased cytotoxic effect of Oxa-BMNP nanoassemblies is probably due to internalization of BMNPs in the tested colon cancer cells.
“probably due to the internalization of BMNPs in the tested colon cancer cells.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
Oxa-BMNPs have a strong interaction with macrophages, revealing toxicity and possibility of aggregation.
“However, their strong interaction with the macrophages revealed toxicity and possibility of aggregation.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
Oxa-BMNP nanoassemblies increased the cytotoxic effect of the drug to a higher level than that caused by soluble oxaliplatin.
“Oxa–BMNP nanoassemblies increased the cytotoxic effect of the drug to even higher level than that caused by soluble Oxa”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
A previous proof of concept showed that BMNPs were biocompatible and could be coupled with oxaliplatin.
“In fact, a previous proof of concept showed that BMNPs were biocompatible and could be coupled with Oxaliplatin (Oxa) [14].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
There was a strong interaction of the Oxa-BMNP nanoassemblies with macrophages, reducing the viability of these cells.
“However, as a drawback, there was a strong interaction of the nanoassemblies with the macrophages thus reducing the viability of these cells.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
Oxa-BMNPs have been previously demonstrated to efficiently reduce the IC50 compared to soluble Oxa.
“MamC-mediated biomimetic magnetic nanoparticles coupled with Oxa (Oxa-BMNPs) have been previously demonstrated to efficiently reduce the IC50 compared to that of soluble Oxa.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The Oxa-BMNPs nanoassemblies used in the present study have been previously characterized in Jabalera et al.
“The Oxa-BMNPs nanoassemblies used in the present study have been previously characterized in Jabalera et al. [14].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The use of BMNPs as drug nanocarriers and hyperthermia agents has the advantage over other systems of potentiating the cytotoxic effect by combined chemotherapy and magnetic hyperthermia.
“and (2) the potentiation of the cytotoxic effect by using a combined therapy based on chemotherapy and magnetic hyperthermia [14].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The use of BMNPs as drug nanocarriers and hyperthermia agents has the advantage over other systems of magnetic guidance allowing control of where the drug is delivered and its concentration at the target.
“The use of our BMNPs as drug nanocarriers (Oxa) and as hyperthermia agents have the advantage over the abovementioned systems of: (1) the magnetic guidance allow both the control of where the drug is delivered and the concentration of the drug at the target thanks to possibility of a magnetic guidance”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
MamC-mediated biomimetic nanoparticles (BMNPs) have demonstrated potential as promising drug nanocarriers.
“MamC-mediated biomimetic nanoparticles (here referred as BMNPs) have demonstrated their potential as promising drug nanocarriers [5,6,14,15]”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
MamC-mediated BMNPs have been proposed as efficient nanocarriers of a number of molecules, offering crucial advantages over inorganically synthesized magnetic nanoparticles.
“Therefore, these MamC-mediated BMNPs have been proposed as efficient nanocarriers [5,6,14,15] of a number of molecules offering crucial advantages over the use of inorganically synthesized magnetic nanoparticles to this end.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The reduction of the IC50 with the new nanoformulations (Oxa-BMLs and Oxa-BMLs-PEG) is not as pronounced as it was with the Oxa-BMNPs nanoassemblies of previous works.
“The reduction of the IC50 with the new nanoformulations (Oxa-BMLs and Oxa-BMLs-PEG) is not as pronounced as it was with the Oxa-BMNPs nanoassemblies of previous works described by Jabalera et al. [14]”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The lower internalization of BMLs compared to uncovered BMNPs can be related to the great reduction of toxicity observed in normal CCD18 versus previous studies.
“Finally, the lower internalization of BMLs compared to uncovered BMNPs [14] can also be related with the great reduction of toxicity observed in the normal CCD18 versus previous studies [14].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
The addition of a lipid cover to the nanoparticles improves their dispersion, eliminating the agglutination of erythrocytes previously observed.
“In comparison to our previous studies [14], the addition of a lipid cover to the nanoparticles improve their dispersion, eliminating the agglutination of erythrocytes previously observed.”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
BMLs-PEG were non-toxic to WBC both at 1 and 12 h of exposure, by contrast to uncovered NPs, and viability recovered in most treatments after 12 h of exposure.
“our results demonstrated that BMLs-PEG were non-toxic to WBC both at 1 and 12 h of exposure by contrast to uncovered NPs in addition to observing a recovery of viability in most treatments after 12 h of exposure such as has been previously described [14].”
From Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 58
- Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
- Banerjee, 2017, Strategies for targeted drug delivery in treatment of colon cancer: Current trends and future perspectives, Drug Discov. Today, 22, 1224, 10.1016/j.drudis.2017.05.006 · DOI · Paper page
- Simon, 2016, Colorectal cancer development and advances in screening, Clin. Interv. Aging, 11, 967, 10.2147/CIA.S109285 · DOI
- Ferlay, 2018, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018, Eur. J. Cancer, 103, 356, 10.1016/j.ejca.2018.07.005 · DOI
- Siegel, 2018, Cancer statistics, 2018: Cancer Statistics, 2018, CA A Cancer J. Clin., 68, 7, 10.3322/caac.21442 · DOI
- Hubbard, 2013, Adolescent and young adult colorectal cancer, J. Natl. Compr. Cancer Netw., 11, 1219, 10.6004/jnccn.2013.0144 · DOI
- Dienstmann, 2015, Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients, J. Clin. Oncol., 33, 1787, 10.1200/JCO.2014.60.0213 · DOI
- Ychou, 2013, A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial, Ann. Surg. Oncol., 20, 4289, 10.1245/s10434-013-3217-x · DOI
- Betsiou, 2007, Adsorption of oxaliplatin by hydroxyapatite, Bioautomation, 8, 138
- Carrato, 2002, Oxaliplatin: Results in colorectal carcinoma, Crit. Rev. Oncol. Hematol., 44, 29, 10.1016/S1040-8428(01)00192-5 · DOI
- Betsiou, 2012, Adsorption and release of gemcitabine hydrochloride and oxaliplatin by hydroxyapatite, Ceram. Int., 38, 2719, 10.1016/j.ceramint.2011.11.040 · DOI
- Dunn, 1997, Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines, Investig. New Drugs, 15, 109, 10.1023/A:1005800520747 · DOI
- Ades, 2009, Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice, Oncology, 23, 162
- Kotelevets, 2016, Nanotechnologies for the treatment of colon cancer: From old drugs to new hope, Int. J. Pharm., 514, 24, 10.1016/j.ijpharm.2016.06.005 · DOI
- Wang, 2012, Nanoparticle delivery of cancer drugs, Annu. Rev. Med., 63, 185, 10.1146/annurev-med-040210-162544 · DOI
- Sau, 2018, Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment, J. Control. Release, 274, 24, 10.1016/j.jconrel.2018.01.028 · DOI
- Dobson, 2006, Magnetic micro- and nano-particle-based targeting for drug and gene delivery, Nanomedicine, 1, 31, 10.2217/17435889.1.1.31 · DOI
- Datta, 2016, Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich’s “magic (nano)bullet” for cancer theranostics?, Cancer Treat. Rev., 50, 217, 10.1016/j.ctrv.2016.09.016 · DOI · Paper page
- Shubayev, 2009, Magnetic nanoparticles for theragnostics, Adv. Drug Deliv. Rev., 61, 467, 10.1016/j.addr.2009.03.007 · DOI
- Pankhurst, 2003, Applications of magnetic nanoparticles in biomedicine, J. Phys. D Appl. Phys., 36, R167, 10.1088/0022-3727/36/13/201 · DOI
- Prozorov, 2013, Novel magnetic nanomaterials inspired by magnetotactic bacteria: Topical review, Mater. Sci. Eng. R Rep., 74, 133, 10.1016/j.mser.2013.04.002 · DOI · Paper page
- Karimi, 2016, Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems, Chem. Soc. Rev., 45, 1457, 10.1039/C5CS00798D · DOI
- Faure, 2011, Heat production by bacterial magnetosomes exposed to an oscillating magnetic field, J. Phys. Chem. C, 115, 18, 10.1021/jp104580t · DOI
- Kolhatkar, 2013, Tuning the magnetic properties of nanoparticles, Int. J. Mol. Sci., 14, 15977, 10.3390/ijms140815977 · DOI
- Amemiya, 2007, Controlled formation of magnetite crystal by partial oxidation of ferrous hydroxide in the presence of recombinant magnetotactic bacterial protein Mms6, Biomaterials, 28, 5381, 10.1016/j.biomaterials.2007.07.051 · DOI
- Prozorov, 2007, Protein-mediated synthesis of uniform superparamagnetic magnetite nanocrystals, Adv. Funct. Mater., 17, 951, 10.1002/adfm.200600448 · DOI
- Staniland, 2016, Crystallizing the function of the magnetosome membrane mineralization protein Mms6, Biochem. Soc. Trans., 44, 883, 10.1042/BST20160057 · DOI
- Prozorov, 2015, Size control of in vitro synthesized magnetite crystals by the MamC protein of Magnetococcus marinus strain MC-1, Appl. Microbiol. Biotechnol., 99, 5109, 10.1007/s00253-014-6326-y · DOI · Paper page
- Nudelman, 2016, Structure—Function studies of the magnetite-biomineralizing magnetosome-associated protein MamC, J. Struct. Biol., 194, 244, 10.1016/j.jsb.2016.03.001 · DOI
- Zarivach, 2017, Magnetite nanoparticles biomineralization in the presence of the magnetosome membrane protein MamC: Effect of protein aggregation and protein structure on magnetite formation, Cryst. Growth Des., 17, 1620, 10.1021/acs.cgd.6b01643 · DOI · Paper page
- Peigneux, 2018, pH-Dependent adsorption release of doxorubicin on MamC-biomimetic magnetite nanoparticles, Langmuir, 34, 13713, 10.1021/acs.langmuir.8b03109 · DOI · Paper page
- Dutta, 2012, Development of oxaliplatin encapsulated in magnetic nanocarriers of pectin as a potential targeted drug delivery for cancer therapy, Results Pharma Sci., 2, 38, 10.1016/j.rinphs.2012.05.001 · DOI
- Munaweera, 2015, Chemoradiotherapeutic Magnetic Nanoparticles for Targeted Treatment of Nonsmall Cell Lung Cancer, Mol. Pharm., 12, 3588, 10.1021/acs.molpharmaceut.5b00304 · DOI
- Ahmed, 2015, Hyperthermia: An effective strategy to induce apoptosis in cancer cells, Apoptosis, 20, 1411, 10.1007/s10495-015-1168-3 · DOI
- Ortiz, 2015, Poly(butylcyanoacrylate) and Poly(ε-caprolactone) Nanoparticles Loaded with 5-Fluorouracil Increase the Cytotoxic Effect of the Drug in Experimental Colon Cancer, AAPS J., 17, 918, 10.1208/s12248-015-9761-5 · DOI
- Evans, 2013, Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs, J. Vis. Exp., 73, e50166
- Assadian, 2017, Toxicity of copper oxide (CuO) nanoparticles on human blood lymphocytes, Biol. Trace Elem. Res., 184, 350, 10.1007/s12011-017-1170-4 · DOI
- Lorente, 2018, Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy, Colloids Surf. B Biointerfaces, 171, 553, 10.1016/j.colsurfb.2018.07.070 · DOI
- Iafisco, 2016, Superparamagnetic iron-doped nanocrystalline apatite as a delivery system for doxorubicin, J. Mater. Chem. B, 4, 57, 10.1039/C5TB01524C · DOI
- Wu, 2013, Adsorption properties of doxorubicin hydrochloride onto graphene oxide: Equilibrium, kinetic and thermodynamic studies, Materials, 6, 2026, 10.3390/ma6052026 · DOI
- Geisow, 1984, pH in the endosome: Measurements during pinocytosis and receptor-mediated endocytosis, Exp. Cell Res., 150, 36, 10.1016/0014-4827(84)90699-2 · DOI
- Iglesias, G.R., Reyes-Ortega, F., Checa Fernandez, B.L., and Delgado, Á.V. (2018). Hyperthermia-Triggered Gemcitabine Release from Polymer-Coated Magnetite Nanoparticles. Polymers, 10. · DOI
- Felfoul, 2016, Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions, Nat. Nanotechnol., 11, 941, 10.1038/nnano.2016.137 · DOI
- Taherkhani, 2014, Covalent Binding of Nanoliposomes to the Surface of Magnetotactic Bacteria for the Synthesis of Self-Propelled Therapeutic Agents, ACS Nano, 8, 5049, 10.1021/nn5011304 · DOI
- Manna, 2017, Lineage-specific proteins essential for endocytosis in trypanosomes, J. Cell Sci., 130, 1379, 10.1242/jcs.191478 · DOI
- Mercanti, 2010, Transmembrane domains control exclusion of membrane proteins from clathrin-coated pits, J. Cell Sci., 123, 3329, 10.1242/jcs.073031 · DOI
- Bae, 2011, The effect of static magnetic fields on the aggregation and cytotoxicity of magnetic nanoparticles, Biomaterials, 32, 9401, 10.1016/j.biomaterials.2011.08.075 · DOI
- Nosrati, 2018, Preparation of magnetic albumin nanoparticles via a simple and one-pot desolvation and co-precipitation method for medical and pharmaceutical applications, Int. J. Biol. Macromol., 108, 909, 10.1016/j.ijbiomac.2017.10.180 · DOI
- White, 2015, Functionalized iron oxide nanoparticles for controlling the movement of immune cells, Nanoscale, 7, 7780, 10.1039/C3NR04421A · DOI
- Dakwar, 2013, Bolaamphiphilic vesicles encapsulating iron oxide nanoparticles: New vehicles for magnetically targeted drug delivery, Int. J. Pharm., 450, 241, 10.1016/j.ijpharm.2013.04.017 · DOI
- Jin, 2016, Magnetic enrichment of dendritic cell vaccine in lymph node with fluorescent-magnetic nanoparticles enhanced cancer immunotherapy, Theranostics, 6, 2000, 10.7150/thno.15102 · DOI
- Lu, Y.-J., Lin, P.-Y., Huang, P.-H., Kuo, C.-Y., Shalumon, K.T., Chen, M.-Y., and Chen, J.-P. (2018). Magnetic graphene oxide for dual targeted delivery of doxorubicin and photothermal therapy. Nanomaterials, 8. · DOI
- Schlenk, 2017, Comprehensive analysis of the in vitro and ex ovo hemocompatibility of surface engineered iron oxide nanoparticles for biomedical applications, Arch. Toxicol., 91, 3271, 10.1007/s00204-017-1968-z · DOI · Paper page
- Lum, 1986, Transferrin synthesis by inducer T lymphocytes, J. Clin. Investig., 77, 841, 10.1172/JCI112381 · DOI
- Wang, 2011, The changes of T lymphocytes and cytokines in ICR mice fed with Fe3O4 magnetic nanoparticles, Int. J. Nanomed., 6, 605
- Chen, 2010, The effect of magnetic nanoparticles of Fe3O4 on immune function in normal ICR mice, Int. J. Nanomed., 5, 593, 10.2147/IJN.S12162 · DOI
- Park, 2014, Magnetic iron oxide nanoparticles induce autophagy preceding apoptosis through mitochondrial damage and ER stress in RAW264.7 cells, Toxicol. In Vitro, 28, 1402, 10.1016/j.tiv.2014.07.010 · DOI · Paper page
- Ilinskaya, 2013, Nanoparticles and the blood coagulation system. Part II: Safety concerns, Nanomedicine, 8, 969, 10.2217/nnm.13.49 · DOI
Cited by
Sorted by citations
Garcia-Pinel, B., Jabalera, Y., Ortiz, R., Cabeza, L., Jimenez-Lopez, C., Melguizo, C., & Prados, J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060589 · Cited by 40
Self-citation
Metadata
- Authors
- Jabalera, Y., Garcia-Pinel, B., Ortiz, R., Iglesias, G., Cabeza, L., Prados, J., Jimenez-Lopez, C., & Melguizo, C.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-08-06
- Volume
- 11
- Issue
- 8
- Pages
- 395
- ISSN
- 1999-4923
- PMC
- PMC6723246
- Cited by
- 49
- References
- 0
- Language
- en
- Funders
- Ministerio de Economía y Competitividad (CGL2016-76723)
- Consejería de Salud de la Junta de Andalucía (PI-0476-2016, PI-0102-2017)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
